Variables | All patients (N = 217) | miR-224-3p ≥ median (N = 109) | miR-224-3p < median (N = 108) | P | miR-155-5p ≥ median (N = 109) | miR-155-5p < median (N = 108) | P |
---|---|---|---|---|---|---|---|
Clinical characteristics | |||||||
Age (y) | 54 (47–63) | 55 (48–63) | 53 (46–63) | 0.38 | 56 (48–67) | 52 (46–63) | 0.22 |
Male, n (%) | 191 (88) | 99 (90.8) | 92 (85.2) | 0.20 | 93 (85.3) | 98 (90.7) | 0.21 |
Body mass index, kg/m2 | 24.2 (22.2–26.9) | 23.8 (21.5–26.8) | 24.8 (22.5–27.1) | 0.33 | 24.2(21.4–27.1) | 23.8 (22.4–26.6) | 0.62 |
CAD risk factors, n (%) | |||||||
Hypertension | 129 (59.4) | 68 (62.4) | 61 (56.5) | 0.37 | 66 (60.6) | 63 (58.3) | 0.73 |
Diabetes mellitus | 65 (30) | 31 (28.4) | 34 (31.5) | 0.62 | 30 (27.5) | 35 (32.4) | 0.43 |
Dyslipidemia | 53 (24.4) | 29 (26.6) | 24 (22.2) | 0.45 | 28 (25.7) | 25 (23.1) | 0.66 |
Smoking | 168 (77.4) | 86 (78.9) | 82 (75.9) | 0.60 | 81 (74.3) | 87 (80.6) | 0.27 |
Family History | 34 (15.7) | 14 (12.8) | 20 (18.5) | 0.25 | 19 (17.6) | 15 (13.8) | 0.43 |
Symptom onset > 6 h, n (%) | 105 (48.4) | 48 (44.0) | 57 (52.8) | 0.19 | 48 (44.0) | 57 (52.8) | 0.19 |
Anterior MI, n (%) | 112 (51.6) | 56 (51.4) | 56 (51.9) | 0.94 | 58 (53.2) | 54 (50.0) | 0.63 |
TIMI risk score > 4, n (%) | 61 (28.1) | 31 (28.4) | 30 (27.8) | 0.91 | 33 (30.3) | 28 (25.9) | 0.47 |
Killip class II–IV, n (%) | 41 (18.9) | 17 (15.6) | 24 (22.2) | 0.21 | 17 (15.6) | 24 (22.2) | 0.21 |
Medication at 24 h, n (%) | |||||||
Salicylic acid | 217 (100) | 109 (100) | 108 (100) | NA | 109 (100) | 108 (100) | NA |
Clopidogrel | 164 (75.6) | 83 (76.1) | 81 (75.0) | 0.84 | 81 (74.3) | 83 (76.9) | 0.66 |
Ticagrelor | 53 (24.4) | 26 (23.9) | 27 (25) | 0.84 | 28 (25.7) | 25 (23.1) | 0.66 |
ACE-inhibitor | 60 (27.6) | 24 (22.0) | 36 (33.3) | 0.06 | 28 (25.7) | 32 (29.6) | 0.51 |
Beta-blocker | 4 (1.8) | 2 (1.8) | 1 (1.9) | 1.00 | 1 (0.9) | 3 (2.8) | 0.30 |
Statin | 212 (97.7) | 106 (97.2) | 106 (98.1) | 1.00 | 107 (98.2) | 105 (97.2) | 0.68 |
Anticoagulation, n (%) | 66 (30.4) | 35 (32.1) | 31 (28.7) | 0.58 | 33 (30.2) | 33 (30.5) | 0.96 |
Medications at discharged, n (%) | |||||||
Salicylic acid | 214 (28.6) | 108 (99.1) | 106 (98.1) | 0.62 | 108 (99.1) | 106 (98.1) | 0.62 |
Clopidogrel | 164 (75.6) | 86 (78.9) | 78 (72.2) | 0.25 | 82 (75.9) | 82 (75.9) | 0.90 |
Ticagrelor | 52 (24.1) | 23 (21.6) | 29 (26.9) | 0.34 | 27 (24.8) | 25 (23.4) | 0.80 |
ACE-inhibitor | 189 (87.1) | 95 (87.2) | 94 (87.0) | 0.97 | 95 (87.2) | 94 (87.0) | 0.97 |
Beta-blocker | 188 (86.2) | 95 (87.2) | 93 (86.1) | 0.81 | 96 (88.1) | 92 (85.2) | 0.53 |
Statin | 217 (100) | 109 (100) | 108 (100) | NA | 109 (100) | 108 (100) | NA |
Echocardiography data | |||||||
LVEF, (%) | 48 (40–56) | 48 (41–56) | 48 (40–56) | 0.36 | 50 (41–57.7) | 46 (39–55) | 0.02 |
Laboratory characteristics | |||||||
Hemoglobin, g/dl | 14.4 (13–15.4) | 14.6 (13.3–15.5) | 13.9 (12.8–15.2) | 0.48 | 14.3 (13.1–15.4) | 14.6 (13–15.3) | 0.30 |
Leukocyte count, /ul | 13,230 (11,050–16,130) | 14,090 (11,140–15,990) | 12,905 (10,962.5–16,265) | 0.68 | 13,570 (10,992.5–16,255) | 13,230 (11,250–16,130) | 0.64 |
Baseline creatinine > 1.3 mg/dl, n (%) | 38 (16.6) | 13 (11.9) | 23 (21.3) | 0.06 | 18 (16.5) | 18 (16.7) | 0.97 |
Admission blood glucose level, mg/dl | 141 (117–201) | 138 (115–195) | 144.5 (118.2–207.2) | 0.44 | 135 (115–199.7) | 144 (119–202) | 0.11 |
Initial Troponin T, ng/L | 398 (155–1021) | 418 (168–1714) | 389 (139.2–691) | 0.16 | 319 (152.2–1256) | 417 (155–962) | 0.79 |
Primary PCI characteristics | |||||||
Baseline TIMI flow, n (%) | |||||||
0 | 160 (73.7) | 77 (70.6) | 83 (76.9) | 0.29 | 77 (70.6) | 83 (76.9) | 0.29 |
1 | 11 (5.1) | 5 (4.6) | 6 (5.6) | 0.74 | 6 (5.5) | 5 (4.6) | 0.76 |
2 | 30 (13.8) | 19 (17.4) | 11 (10.2) | 0.12 | 17 (15.6) | 13 (12.0) | 0.44 |
3 | 16 (7.4) | 8 (7.3) | 8 (7.4) | 0.98 | 9 (8.3) | 7 (6.5) | 0.61 |
Final TIMI flow, n (%) | |||||||
0 | 2 (0.9) | 0 | 2 (1.9) | 0.34 | 1 (0.9) | 1 (0.9) | 1.00 |
1 | 16 (7.4) | 8 (7.3) | 8 (7.4) | 0.98 | 10 (9.2) | 6 (5.6) | 0.30 |
2 | 98 (45.2) | 57 (52.3) | 41 (38.0) | 0.03 | 48 (44.0) | 50 (46.3) | 0.73 |
3 | 101 (46.5) | 44 (40.4) | 57 (52.8) | 0.06 | 50 (45.9) | 51 (47.2) | 0.82 |
Thrombus grade 4&5, n (%) | 169 (77.9) | 83 (76.1) | 86 (79.6) | 0.53 | 84 (77.1) | 85 (78.7) | 0.77 |
Door-to-device time, min | 64 (54–79) | 67 (56–80) | 63 (53–73 | 0.07 | 68 (56.5–83.7) | 62 (52–73) | 0.01 |
Procedural time, min | 40 (31–55) | 40 (31–57) | 40 (30–52) | 0.39 | 40 (31.2- 56.5) | 41 (29–52) | 0.59 |
Radial access, n (%) | 184 (84.8) | 90 (82.6) | 94 (87.0) | 0.35 | 89 (81.7) | 95 (88) | 0.19 |
Balloon predilation, n (%) | 208 (95.9) | 105(96.3) | 103 (95.4) | 0.74 | 103 (94.5) | 105 (97.2) | 0.49 |
Manual thrombectomy, n (%) | 3 (2.8) | 3 (2.8) | 0 | 0.24 | 2 (1.8) | 1 (0.9) | 1.00 |
Intracoronary eptifibatide, n (%) | 10 (4.6) | 5 (4.6) | 5 (4.6) | 1.00 | 4 (3.7) | 6 (5.6) | 0.53 |
Infarct related artery, n (%) | |||||||
Left main | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LAD | 113 (52.1) | 56 (51.4) | 57 (52.8) | 0.83 | 57 (52.3) | 56 (51.9) | 0.94 |
LCX | 7 (3.2) | 7 (6.4) | 0 (0) | 0.01 | 1 (0.9) | 6 (5.5) | 0.05 |
RCA | 97 (44.7) | 46 (42.2) | 51 (47.2) | 0.45 | 46 (42.2) | 51 (47.2) | 0.45 |
Coronary involvement, n (%) | |||||||
1-Vessel disease | 68 (31.1) | 32 (29.4) | 36 (33.3) | 0.52 | 35 (32.1) | 33 (30.6) | 0.80 |
2-Vessel disease | 66 (30.4) | 35 (32.1) | 31 (28.7) | 0.58 | 33 (30.6) | 33 (30.3) | 0.96 |
3-Vessel disease | 73 (33.6) | 40 (36.7) | 33 (30.6) | 0.33 | 38 (34.9) | 35 (32.4) | 0.70 |
Left Main disease | 10 (4.6) | 2 (1.8) | 8 (7.4) | 0.05 | 3 (2.8) | 7 (6.5) | 0.74 |
Use of mechanical ventilation, n (%) | 9 (4.1) | 4 (3.7) | 5 (4.6) | 0.74 | 4 (3.7) | 5 (4.6) | 0.74 |
Use of DES, n (%) | 213 (98.2) | 107 (98.2) | 106 (98.1) | 1.00 | 107 (98.2) | 106 (9.1) | 1.00 |